The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 131-139

  Yin, Jibin ^a   Liu, Bingrong ^a   Li, Baoxin ^a   Liu, Zhaojun ^a   Xie, Xinyu ^b   Lv, Zhiwu ^a   Gao, Shanling ^a   Guang, Jingming ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b BEIJING CHUIYANGLIU HOSPITAL   (China)

Author keywords

c Met tyrosine kinase; Celecoxib; Doxorubicin; Hepatocellular carcinoma; Hepatocyte growth factor receptor; Orthotopic mouse model; Proliferating cell nuclear antigen

Indexed keywords

CELECOXIB; CELL NUCLEUS ANTIGEN; DOXORUBICIN; SCATTER FACTOR RECEPTOR; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; WEIGHT GAIN;

EID: 79952389833     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587803     Document Type: Article

References (33)

1. Shariff, M. I.; Cox, I. J.; Gomaa, A. I.; Khan, S. A.; Gedroyc, W.; Taylor-Robinson, S. D. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 3:353-367; 2009.
2. Sherman, M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 30:3-16; 2010.
3. Fung, J.; Lai, C. L.; Yuen, M. F. Hepatitis B and C virus- related carcinogenesis. Clin. Microbiol. Infect. 15:964-970; 2009.
4. Artinyan, A.; Mailey, B.; Sanchez-Luege, N.; Khalili, J.; Sun, C. L.; Bhatia, S.; Wagman, L. D.; Nissen, N.; Colquhoun, S. D.; Kim, J. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 116:1367-1377; 2010.
5. Al-Rawashdeh, F. Y.; Scriven, P.; Cameron, I. C.; Vergani, P. V.; Wyld, L. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 22(9):1099-1015; 2010.
6. Schönthal, A. H.; Chen, T. C.; Hofman, F. M.; Louie, S. G.; Petasis, N. A. Celecoxib analogs that lack COX-2 inhibitory function: Preclinical development of novel anti-cancer drugs. Expert Opin. Investig. Drugs 17:197-208; 2008.
7. Harris, R. E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17:55-67; 2009.
8. Nagahara, T.; Okano, J.; Murawaki, Y. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase- 2 inhibitor, on human liver cancer cells. Oncol. Rep. 18:1281-1290; 2007.
9. Yin, J. B.; Liu, T. F.; Liu, W.; Zhao, R. B. Effects of NS-398 on the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinase-2 (TIMP-2). Chin. J. Digest. 26:262-263; 2006.
10. Xie, H.; Gao, L.; Chai, N.; Song, J.; Wang, J.; Song, Z.; Chen, C.; Pan, Y.; Zhao, L.; Sun, S.; Wu, K.; Feitelson, M. A.; Liu, J.; Fan, D. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol. Carcinog. 48:56-65; 2009.
11. Baek, J. Y.; Hur, W.; Wang, J. S.; Bae, S. H.; Yoon, S. K. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J. Gastroenterol. 13: 1175-1181; 2007.
12. Tuynman, J. B.; Vermeulen, L.; Boon, E. M.; Kemper, K.; Zwinderman, A. H.; Peppelenbosch, M. P.; Richel, D. J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68:1213-1220; 2008.
13. Liu, N. B.; Peng, T.; Pan, C.; Yao, Y. Y.; Shen, B.; Leng, J. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. World J. Gastroenterol. 11:6281-6287; 2008.
14. Mazzanti, R.; Platini, F.; Bottini, C.; Fantappiè, O.; Solazzo, M.; Tessitore, L. Down-regulation of the HGF/ MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem. Pharmacol. 78:21-32; 2009.
15. Cusimano, A.; Azzolina, A.; Iovanna, J. L.; Bachvarov, D.; McCubrey, J. A.; D'Alessandro, N.; Montalto, G.; Cervello, M. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 9:1399-1410; 2010.
16. Roy, K. R.; Reddy, G. V.; Maitreyi, L.; Agarwal, S.; Achari, C.; Vali, S.; Reddanna, P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol. 65:903-911; 2010.
17. Cui, W.; Yu, C. H.; Hu, K. Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 11:8213-8221; 2005.
18. Cui, W.; Hu, S. X.; Tang, Z. Y.; Hu, K. Q. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase- 2 (COX-2)-expressing versus COX-2-deleted human HXX xenografts in nude mice. Anticancer Drugs 19: 891-897; 2008.
19. Liu, X.; Newton, R. C.; Scherle, P. A. Developing c-MET pathway inhibitors for cancer therapy: Progress and challenges. Trends Mol. Med. 16:37-45; 2010.
20. Porter, J. Small molecule c-Met kinase inhibitors: A review of recent patents. Expert Opin. Ther. Pat. 20:159-177; 2010.
21. Osada, S.; Kanematsu, M.; Imai, H.; Goshima, S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55:544-549; 2008.
22. Li, N.; Fu, H.; Tie, Y.; Hu, Z.; Kong, W.; Wu, Y.; Zheng, X. miR-34a inhibits migration and invasion by down- regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275:44-53; 2009.
23. Ke, A. W.; Shi, G. M.; Zhou, J.; Wu, F. Z.; Ding, Z. B.; Hu, M. Y.; Xu, Y.; Song, Z. J.; Wang, Z. J.; Wu, J. C.; Bai, D. S.; Li, J. C.; Liu, K. D.; Fan, J. Role of everexpresion of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491-503; 2009.
24. Xie, B.; Xing, R.; Chen, P.; Gou, Y.; Li, S.; Xiao, J.; Dong, J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J. Surg. Res. 162(2):231-238; 2010.
25. Tuynman, J. B.; Buskens, C. J.; Kemper, K.; ten Kate, F. J.; Offerhaus, G. J.; Richel, D. J.; van Lanschot, J. J. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 242:840-849; 2005.
26. Siegfried, J. M.; Gubish, C. T.; Rothstein, M. E.; Queiroz de Oliveira, P. E.; Stabile, L. P. Cyclooxygenase-2 inhibi- tion inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68:12-13; 2008.
27. Zuo, Z. H.; Li, Z. R.; Zhou, X.; Ouyang, Y. Z.; Zhou, Z. Y.; Zeng, L. Inhibitory effects of cyclooxygenase-2 in- hibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice. Ai Zheng 25:414-420; 2006.
28. Yuan, S.; Zhang, X.; Lu, L.; Xu, C.; Yang, W.; Ding, J. Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anti-cancer Drugs 15:641-646; 2004.
29. Zhu, Z. F.; Chen, L. J.; Lu, R.; Jia, J.; Liang, Y.; Xu, Q.; Zhou, C. L.; Wang, L.; Wang, S.; Yao, Z. Tripeptide tyroserleutide plus doxorubicin; therapeutic synergy and side effect attenuation. BMC Cancer 8:342; 2008.
30. Paunesku, T.; Mittal, S.; Protic, M.; Oryhon, J.; Korolev, S. N.; Joachimiak, A.; Woloschak, G. E. Proliferating cell nuclear antigen (PCNA): Ringmaster of the genome. Int. J. Radiat. Biol. 77:1007-1021; 2001.
31. Canadas, I.; Rojo, F.; Arumi-Uria, M.; Rovira, A.; Abanell, J.; Arriola, E. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin. Transl. Oncol. 12:253-260; 2010.
32. Cecchi, F.; Rabe, D. C.; Bottaro, D. P. Targeting the HGF-Met signaling pathway in cancer. Eur. J. Cancer 46: 1260-1270; 2010.
33. Breuhahn, K.; Logerich, T.; Schirmacher, P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787-3800; 2006.